Linda Yaccarino, CEO of X Corp., attends the Milken Institute Global Conference 2025 in Beverly Hills, California, U.S., May 5, 2025.
Mike Blake | Reuters
Linda Yaccarino, the previous chief executive of Elon Musk’s social media platform X, is pivoting into health care.
The digital health company eMed Population Health on Tuesday announced it has appointed Yaccarino as its recent CEO. EMed is developing a population health management platform for the blockbuster weight reduction and diabetes drugs called GLP-1s, the corporate said. It had raised a complete of $22 million as of 2022, in accordance with PitchBook.
Yaccarino, who rose to the highest of NBCUniversal’s global promoting business before joining X, will help eMed establish “game-changing partnerships” and navigate complex markets, the corporate said.
“The healthcare industry has been disrupted by technology, but not yet completely transformed by it,” Yaccarino said in a press release. “There’s a chance to mix technology, lifestyle, and data in a brand new powerful way through the digital channels that impact consumers directly in ways in which have never been done before.”
EMed is a component of the growing group of digital health corporations which are attempting to capitalize on the sky-high demand for GLP-1s. Goldman Sachs analysts expect 15 million U.S. adults to be on anti-obesity drugs by 2030, they usually predict the industry could reach $100 billion in annual revenue by that point.
Yaccarino stepped down from her role as CEO at X in July and didn’t disclose a reason for her departure. EMed said she is a “highly sought-after leader” with an “undeniable ability to barter recent partnerships.”
“To be a frontrunner in today’s healthcare marketplace, corporations have to have a fearless tenacity that permits them to not only grow, but to even be brave enough to step forward and redefine a whole industry,” Yaccarino said.
Disclosure: NBCUniversal is the parent company of NBC and CNBC.
